{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:51:33Z","timestamp":1768420293376,"version":"3.49.0"},"reference-count":46,"publisher":"Portland Press Ltd.","issue":"7","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10,1]]},"abstract":"<jats:p>Mineralocorticoid receptors (MRs), which are activated by mineralocorticoids and glucocorticoids, actively participate in mechanisms that affect the structure and function of blood vessels. Although experimental and clinical evidence shows that vascular damage in diabetes is associated with structural alterations in large and small arteries, the role of MR in this process needs further studies. Thus, we tested the hypothesis that MR, through redox-sensitive mechanisms, plays a role in diabetes-associated vascular remodelling. Male, 12\u201314-weeks-old db\/db mice, a model of type\u00a02 diabetes and their non-diabetic counterpart controls (db\/+) were treated with spironolactone (MR antagonist, 50\u00a0mg\/kg\/day) or vehicle for 6\u00a0weeks. Spironolactone treatment did not affect blood pressure, fasting glucose levels or weight gain, but increased serum potassium and total cholesterol in both, diabetic and control mice. In addition, spironolactone significantly reduced serum insulin levels, but not aldosterone levels in diabetic mice. Insulin sensitivity, evaluated by the HOMA (homoeostatic model assessment)-index, was improved in spironolactone-treated diabetic mice. Mesenteric resistance arteries from vehicle-treated db\/db mice exhibited inward hypertrophic remodelling, increased number of smooth muscle cells and increased vascular stiffness. These structural changes, determined by morphometric analysis and with a myography for pressurized arteries, were prevented by spironolactone treatment. Arteries from vehicle-treated db\/db mice also exhibited augmented collagen content, determined by Picrosirius Red staining and Western blotting, increased reactive oxygen species (ROS) generation, determined by dihydroethidium (DHE) fluorescence, as well as increased expression of NAD(P)H oxidases 1 and 4 and increased activity of mitogen-activated protein kinases (MAPKs). Spironolactone treatment prevented all these changes, indicating that MR importantly contributes to diabetes-associated vascular dysfunction by inducing oxidative stress and by increasing the activity of redox-sensitive proteins.<\/jats:p>","DOI":"10.1042\/cs20140758","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T12:06:24Z","timestamp":1431518784000},"page":"533-545","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type\u00a02 diabetes mellitus"],"prefix":"10.1042","volume":"129","author":[{"given":"Marcondes\u00a0Alves\u00a0B.","family":"Silva","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto 14.049-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefany\u00a0Bruno\u00a0A.","family":"Cau","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto 14.049-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rheure\u00a0Alves\u00a0M.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto 14.049-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla\u00a0P.","family":"Manzato","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto 14.049-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla\u00a0B.","family":"Neves","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto 14.049-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago","family":"Bruder-Nascimento","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto 14.049-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola\u00a0Leslie\u00a0Antunes C.","family":"Mestriner","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto 14.049-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto\u00a0C.","family":"Montezano","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G128TA, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie\u00a0Nguyen\u00a0Dinh","family":"Cat","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G128TA, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhian\u00a0M.","family":"Touyz","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G128TA, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita\u00a0C.","family":"Tostes","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Ribeir\u00e3o Preto Medical School, University of S\u00e3o Paulo, Ribeir\u00e3o Preto 14.049-900, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2015,7,3]]},"reference":[{"key":"2021113010485020400_B1","volume-title":"National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States. U.S. Department of Health and Human Services 1\u201312","author":"Centers for Disease Control and Prevention","year":"2011"},{"key":"2021113010485020400_B2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res. Clin. Pr."},{"key":"2021113010485020400_B3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5001\/omj.2012.68","article-title":"Type 2 diabetes mellitus: a review of current trends","volume":"27","author":"Olokoba","year":"2012","journal-title":"Oman Med. J."},{"key":"2021113010485020400_B4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000497580","article-title":"Diabetes mellitus and its treatment","volume":"13","author":"Bastaki","year":"2005","journal-title":"Int. J. Diabetes & Metabolism"},{"key":"2021113010485020400_B5","first-page":"853","article-title":"Endothelial dysfunction in diabetes mellitus","volume":"3","author":"Hadi","year":"2007","journal-title":"Vasc. Health Risk Manag."},{"key":"2021113010485020400_B6","article-title":"Pathophysiology of vascular remodeling in hypertension","author":"Renna","year":"2013","journal-title":"Int. J. Hypertens. doi: 10.1155\/2013\/808353"},{"key":"2021113010485020400_B7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/cvr\/cvn039","article-title":"Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies","volume":"78","author":"Spinetti","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"2021113010485020400_B8","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/918267","article-title":"Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing","author":"Kolluru","year":"2012","journal-title":"Int. J. Vasc. Med. doi: 10.1155\/2012\/918267"},{"key":"2021113010485020400_B9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00125-002-0782-0","article-title":"Vascular targets of redox signalling in diabetes mellitus","volume":"45","author":"Spitaler","year":"2002","journal-title":"Diabetologia"},{"key":"2021113010485020400_B10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0828-282X(06)70314-2","article-title":"Reactive oxygen species and vascular remodeling in hypertension: still alive","volume":"22","author":"Xu","year":"2006","journal-title":"Can. J. Cardiol."},{"key":"2021113010485020400_B11","doi-asserted-by":"publisher","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"2021113010485020400_B12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1262-3636(07)70122-2","article-title":"Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy","volume":"30","author":"Ambroisine","year":"2004","journal-title":"Diabetes Metab."},{"key":"2021113010485020400_B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2012.09.034","article-title":"Aldosterone and angiotensin: role in diabetes and cardiovascular diseases","volume":"697","author":"Patel","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"2021113010485020400_B14","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-\u03b3, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"2021113010485020400_B15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/HYPERTENSIONAHA.109.133710","article-title":"Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress","volume":"54","author":"Briones","year":"2009","journal-title":"Hypertension"},{"key":"2021113010485020400_B16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1152\/ajpheart.00802.2005","article-title":"Alterations in structure and mechanics of resistance arteries from ouabain-induced hypertensive rats","volume":"291","author":"Briones","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113010485020400_B17","doi-asserted-by":"publisher","first-page":"e23337","DOI":"10.1371\/journal.pone.0023337","article-title":"Mesenteric resistance arteries in type\u00a02 diabetic db\/db mice undergo outward remodeling","volume":"6","author":"Souza-Smith","year":"2011","journal-title":"PLoS One"},{"key":"2021113010485020400_B18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1161\/CIRCULATIONAHA.107.748236","article-title":"Endothelium-specific GTP cyclohydrolase I overexpression attenuates blood pressure progression in salt-sensitive low-renin hypertension","volume":"117","author":"Du","year":"2008","journal-title":"Circulation"},{"key":"2021113010485020400_B19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1089\/ars.2009.2831","article-title":"Angiotensin II type\u00a01 receptor-dependent oxidative stress mediates endothelial dysfunction in type\u00a02 diabetic mice","volume":"13","author":"Wong","year":"2010","journal-title":"Antioxid. Redox Signal."},{"key":"2021113010485020400_B20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","article-title":"Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics","volume":"13","author":"Epstein","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"2021113010485020400_B21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J. Hypertens."},{"key":"2021113010485020400_B22","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1291\/hypres.27.781","article-title":"Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist","volume":"27","author":"Takeda","year":"2004","journal-title":"Hypertens. Res."},{"key":"2021113010485020400_B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2840-10-94","article-title":"Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report","volume":"10","author":"Resch","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"2021113010485020400_B24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","article-title":"Spironolactone improves angiotensin-induced vascular changes and oxidative stress","volume":"40","author":"Virdis","year":"2002","journal-title":"Hypertension"},{"key":"2021113010485020400_B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1161\/01.HYP.0000078357.92682.EC","article-title":"Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling","volume":"42","author":"Pu","year":"2003","journal-title":"Hypertension"},{"key":"2021113010485020400_B26","first-page":"1030","article-title":"Small artery remodelling in diabetes","volume":"14","author":"Rosei","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"2021113010485020400_B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph3010001","article-title":"Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: does it really work?","volume":"3","author":"Cravedi","year":"2010","journal-title":"Pharmaceuticals"},{"key":"2021113010485020400_B28","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010485020400_B29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2021113010485020400_B30","first-page":"283","article-title":"Hyperkalemia","volume":"73","author":"Hollander-Rodriguez","year":"2006","journal-title":"Am. Fam. Physician."},{"key":"2021113010485020400_B31","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1097\/01.ju.0000140445.82949.54","article-title":"Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction","volume":"172","author":"Trachtman","year":"2004","journal-title":"J. Urol."},{"key":"2021113010485020400_B32","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2353\/ajpath.2010.090578","article-title":"eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists","volume":"176","author":"Kosugi","year":"2010","journal-title":"Am. J. Pathol."},{"key":"2021113010485020400_B33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1096\/fj.13-245415","article-title":"Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice","volume":"28","author":"Armani","year":"2014","journal-title":"FASEB J."},{"key":"2021113010485020400_B34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00499670","article-title":"Stimulation of aldosterone production in\u00a0vitro and its inhibition by spironolactone","volume":"273","author":"Erbler","year":"1972","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"2021113010485020400_B35","doi-asserted-by":"publisher","first-page":"F78","DOI":"10.1152\/ajprenal.00077.2007","article-title":"Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone","volume":"293","author":"Mej\u00eda-Vilet","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021113010485020400_B36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jep.2013.09.027","article-title":"Anti-hyperglycemic and hypolipidemic effects of Cistanche tubulosa in type\u00a02 diabetic db\/db mice","volume":"150","author":"Xiong","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"2021113010485020400_B37","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/ATVBAHA.111.240697","article-title":"Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor","volume":"32","author":"Sherajee","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010485020400_B38","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2125.2009.03483.x","article-title":"Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism","volume":"68","author":"Nakhjavani","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2021113010485020400_B39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00395-011-0201-0","article-title":"Coronary arterioles in type\u00a02 diabetic (db\/db) mice undergo a distinct pattern of remodeling associated with decreased vessel stiffness","volume":"106","author":"Katz","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"2021113010485020400_B40","first-page":"116","article-title":"Remodeling of resistance vessels in essential hypertension","volume":"44","author":"Zervoudaki","year":"2003","journal-title":"Hellenic J. Cardiol."},{"key":"2021113010485020400_B41","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/aob\/mcq243","article-title":"Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation","volume":"107","author":"Strzalka","year":"2011","journal-title":"Ann. Bot."},{"key":"2021113010485020400_B42","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1210\/jc.2002-021443","article-title":"Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease","volume":"88","author":"Mcfarlane","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021113010485020400_B43","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1161\/ATVBAHA.108.168021","article-title":"Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src\u2013regulated redox-sensitive RhoA pathways","volume":"28","author":"Montezano","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010485020400_B44","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1097\/01.ASN.0000132473.50966.14","article-title":"Mechanisms of hypertension: the expanding role of aldosterone","volume":"15","author":"Freel","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021113010485020400_B45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1152\/physrev.00044.2005","article-title":"The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology","volume":"87","author":"Bedard","year":"2007","journal-title":"Physiol. Rev."},{"key":"2021113010485020400_B46","doi-asserted-by":"publisher","first-page":"792639","DOI":"10.1155\/2011\/792639","article-title":"Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?","volume":"2011","author":"Son","year":"2011","journal-title":"J. Signal Transduct."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/129\/7\/533\/444938\/cs1290533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/129\/7\/533\/444938\/cs1290533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:37:02Z","timestamp":1638272222000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/129\/7\/533\/71558\/Mineralocorticoid-receptor-blockade-prevents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,3]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,10,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20140758","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,3]]}}}